Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated

Protagonist Therapeutics, Inc

Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.
Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.
PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.
Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.
Total potential sales milestones from icotrokinra and rusfertide up to $1.2B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.